Immunotherapy before surgery for recurrent head and neck cancer
Part of Cancer clinical trials.
This trial tests an immunotherapy drug (anti-PD-1) given before surgery for head and neck cancer that has come back or spread. The goal is to see if it helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of head and neck cancer called squamous cell carcinoma (not nasopharyngeal cancer).
- Your cancer has come back or spread, and it can be removed with surgery.
- You have not had immunotherapy (like PD-1/PD-L1 inhibitors) before.
- You are willing to have surgery as part of the trial.
- You are generally in good health (able to do daily activities) and your organs are working well enough.
- You do not have serious autoimmune disease, HIV, active hepatitis B or C, or other major health problems that would make the trial unsafe.
- If you can become pregnant, you must use effective birth control during the trial and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
This trial tests whether giving a combination of immunotherapy drugs (pembrolizumab, N-803, and possibly PD-L1 t-haNK cells) before surgery can help treat head and neck cancer that has not been treated yet. It is for people whose cancer is p16-negative (a specific marker) and is at an intermediate or high risk of coming back.
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
Hear when a new Recurrent Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.